LGM
TRVI icon

Logos Global Management’s Trevi Therapeutics TRVI Stock Holding History

Logos Global Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.1M Sell
1,880,000
-520,000
-22% -$7.56M 1.51% 21
2026
Q1 		$28.6M Buy
2,400,000
+850,000
+55% +$9.52M 1.43% 22
2025
Q4 		$19.4M Sell
1,550,000
-650,000
-30% -$7.51M 1.17% 29
2025
Q3 		$20.1M Buy
2,200,000
+1,350,000
+159% +$10.1M 1.8% 24
2025
Q2 		$4.65M Buy
850,000
+425,285
+100% +$2.65M 0.51% 42
2025
Q1 		$2.67M Sell
424,715
-825,285
-66% -$3.94M 0.47% 31
2024
Q4 		$5.15M Sell
1,250,000
-1,500,000
-55% -$4.8M 0.6% 36
2024
Q3 		$9.19M Sell
2,750,000
-50,000
-2% -$149K 0.99% 31
2024
Q2 		$8.34M Buy
2,800,000
+600,000
+27% +$1.67M 0.67% 39
2024
Q1 		$7.59M Buy
+2,200,000
New +$4.91M 0.61% 39

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Logos Global Management's TRVI Position: Q2 2026 in Review

Logos Global Management reduced its Trevi Therapeutics (TRVI) stake by 22% in Q2 2026, selling an estimated $7.56M and leaving 1,880,000 shares worth $35.1M. The position accounts for 1.51% of the portfolio, ranked #21.

Logos Global Management first reported a position in TRVI in Q1 2024 and has held it in 10 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Logos Global Management held 1,880,000 shares of Trevi Therapeutics worth $35.1M as of Q2 2026.
  • Logos Global Management sold 520,000 Trevi Therapeutics shares in Q2 2026, an estimated $7.56M.
  • Trevi Therapeutics made up 1.51% of Logos Global Management's portfolio in Q2 2026, its #21 holding.
  • Logos Global Management first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.